Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ipsen
Ipsen
Biopharma’s bolt-on bonanza is set to continue
EP Vantage
Thu, 01/12/23 - 10:18 am
M&A
Amgen
AstraZeneca
Bristol Myers Squibb
GSK
Ipsen
Merck
Pfizer
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
BioPharma Dive
Mon, 01/9/23 - 10:43 am
JPMHC 2023
M&A
AstraZeneca
CinCor
Ipsen
Albireo
Chiesi Farmaceutici
Amryt Pharma
Ipsen's rare disease candidate rejected after mounting setbacks, delays
Fierce Biotech
Fri, 12/30/22 - 10:48 am
Ipsen
FDA
palovarotene
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Fierce Biotech
Wed, 12/14/22 - 10:44 am
Exicure
AbbVie
Ipsen
R&D
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate
Endpoints
Tue, 10/25/22 - 11:09 pm
Ipsen
FDA
fibrodysplasia ossificans progressiva
Go or no go? GSK takes its turn with a novel anemia class
EP Vantage
Fri, 09/30/22 - 10:52 am
FDA
GSK
Amicus Therapeutics
AstraZeneca
Novartis
Supernus
JNJ
Ipsen
Y-mAbs Therapeutics
Ipsen becomes the latest pharma to expand in Ireland, with a $50M investment in its facility in Dublin suburbs
Endpoints
Mon, 09/26/22 - 11:23 pm
Ipsen
Ireland
drug manufacturing
ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some
Fierce Biotech
Sun, 09/11/22 - 10:58 pm
ESMO
Pfizer
Ipsen
EZH2 inhibitors
Epizyme
Trick, or treat? FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug
Endpoints
Mon, 08/22/22 - 08:10 pm
Ipsen
FDA
bone disease
palovarotene
PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde
Endpoints
Wed, 08/3/22 - 10:51 am
Ipsen
Onivyde
small cell lung cancer
clinical trials
Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief
Endpoints
Mon, 08/1/22 - 10:51 am
Ipsen
Marengo Therapeutics
TCR immunotherapy
Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen
Fierce Pharma
Wed, 07/13/22 - 10:09 am
Epizyme
SEC
M&A
Ipsen
Ipsen beefs up in oncology, buying US biopharma Epizyme
Pharmaforum
Mon, 06/27/22 - 10:52 am
Ipsen
M&A
Epizye
Tazverik
cancer
oncology
First-quarter biotech risers work hard for the win
EP Vantage
Thu, 04/21/22 - 10:32 am
biotech
AbbVie
Bayer
Ipsen
Lantheus Medical
Ipsen plans sale of consumer health business for €350m
Pharmaforum
Fri, 02/11/22 - 11:40 am
Ipsen
M&A
consumer health
Mayoly Spindler
Ipsen withdraws NDA for rare bone disease treatment less than 3 months after winning priority review
Endpoints
Sat, 08/14/21 - 01:47 pm
Ipsen
FDA
palovarotene
Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases
Pharmaforum
Mon, 08/2/21 - 10:54 am
Ipsen
Exicure
neurodegenerative disease
Ipsen bets up to $363M on another shot at a debilitating condition related to Parkinson's disease
Endpoints
Thu, 07/15/21 - 11:50 pm
Ipsen
levodopa-induced dyskinesia
IRLAB
ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen
Fierce Pharma
Thu, 05/20/21 - 12:15 pm
ASCO 2021
Ipsen
Exelixis
Cabometyx
thyroid cancer
clinical trials
Pages
« first
‹ previous
1
2
3
4
next ›
last »